NCT04210388 - A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

March 9, 2020

Study Completion Date

March 9, 2020

Conditions

Coronary Artery Disease (CAD)

Interventions

DRUG

AZD5718 tablet, Formulation A

Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

DRUG

AZD5718 tablet, Formulation B

Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

DRUG

AZD5718 tablet, Formulation C

Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

DRUG

AZD5718 tablet, Formulation D

Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

DRUG

AZD5718 film-coated tablet, Reference treatment

Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow